Jalen Hurts Expected to Miss Rest of 2026 Season After Blood Clot Diagnosis

The diagnosis is deep vein thrombosis and bilateral pulmonary emboli. The latter describes clots that have traveled from the legs to the lungs, according to the reports detailing the statement. The season absence is consistently described as expected or set to occur, rather than as a separately documented formal roster designation.

Hurts was initially diagnosed in London with a superficial vein thrombosis in his left calf. Further testing and monitoring then led to the current diagnosis involving clots in his leg and both lungs.

The Eagles and Lynn said Hurts is clinically stable and has no significant functional limitations. His treatment involves anticoagulants, commonly described as blood thinners, and he cannot take part in contact activities, including football, while undergoing that treatment.

The same statement said a full recovery is expected and that no long-term effects are anticipated. The reports do not identify the hospital or the precise location where Hurts received treatment.

The medical issue has already altered Philadelphia's plans at quarterback. Tanner McKee took over as the Eagles' starter after Hurts became unavailable, with PBS NewsHour's Associated Press report noting that McKee started against the Carolina Panthers.

Sky Sports, citing NFL Network's Ian Rapoport, and ABC Australia Sport, citing ESPN, reported that Hurts was in a London hospital until 4 a.m. before the Eagles' game against the Jacksonville Jaguars and did not sleep beforehand. Those details remain attributed reports rather than an independently confirmed account in the supplied evidence.

The Eagles' immediate sporting consequence is the loss of their starting quarterback for an expected remainder-of-season absence, while Hurts's treatment restrictions prevent him from returning to contact football during anticoagulation. The available reports establish McKee's current starting role but do not establish who will remain Philadelphia's starter for the entire campaign.